•  
  •  
 

Abstract

Chronic kidney disease (CKD) is still a burden on worldwide health issues affecting about 11-13% of the general population. Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a common complication in CKD, which occurs early in the disease, and progresses as kidney function deteriorates. With declining kidney function, mineral homeostasis becomes progressively dysregulated, including alterations in several parameters such as calcium, phosphate, intact parathyroid hormone (iPTH). Changes in these parameters are associated with bone disorders and vascular abnormalities, which are strongly correlated with increased cardiovascular (CV) morbidity and mortality, and overall mortality. Currently, CKD-MBD and its complication management have been focusing on correcting biochemical and hormonal abnormalities to limit their potential effects. All therapeutic decisions are based on circulating levels of calcium, phosphate and PTH considered together. CKD-MBD management should also be individualized since it might differentially benefit the patients.

References

1. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.2. Bello AK, Alrukhaimi M, Ashuntantang GE, Basnet S, Rotter RC, Douthat WG, et al. Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. Kidney Int Suppl. 2017;7(2):122-9.3. Fukagawa M, Komaba H. Chronic kidney disease-mineral and bone disorder in Asia. Kidney Dis (Basel). 2017;3(1):1-7.4. Staude H, Jeske S, Schmitz K, Warncke G, Fischer DC. Cardiovascular risk and mineral bone disorder in patients with chronic kidney disease. Kidney Blood Press Res. 2013;37(1):68-83.5. Hedgeman E, Lipworth L, Lowe K, Saran R, Do T, Fryzek J. International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data. Int J Nephrol. 2015;2015:184321.6. Waziri B, Duarte R, Naicker S. Chronic kidney disease-mineral and bone disorder (CKD-MBD): current perspectives. Int J Nephrol Renovasc Dis. 2019;12:263-76.7. Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2017 clinical practice guideline for diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59.8. Beto J, Bhatt N, Gerbeling T, Patel C, Drayer D. Overview of the 2017 KDIGO CKD-MBD update: practice implications for adult hemodialysis patients. J Ren Nutr. 2019;29(1):2-15.9. Hou YC, Lu CL, Lu KC. Mineral bone disorders in chronic kidney disease. Nephrology (Carlton). 2018;23(Suppl 4):88-94.10. Floege J, Drueke TB. Mineral and bone disorder in chronic kidney disease: pioneering studies. Kidney Int. 2020;98(4):807-11.11. Hruska KA, Seifert M. Pathophysiology of chronic kidney disease mineral bone disorder (CKD-MBD). In: Clifford J. Rosen MD, editors. Primer on the metabolic bone diseases and disorers of mineral metabolism, eight edition. Hoboken, New Jersey: Wiley; 2013. p.632-6.12. Nowak KL, Chonchol M. Management of mineral and bone disorders in chronic kidney disease. Chronic Renal Dis. 2020;2:1013-33.13. Lewis R. Mineral and bone disorders in chronic kidney disease: new insights into mechanism and management. Ann Clin Biochem. 2012;49(Pt 5):432-40.14. Cozzolino M, Urena-Torres P, Vervloet MG, Brandenburg V, Bover J, Goldsmith D, et al. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? Nephrol Dial Transplant. 2014;29(10):1815-20.15. Fishbane SN, Nigwekar S. Phosphate absorption and hyperphosphatemia management in kidney disease: a physiology-based review. Kidney Med. 2021;3(6):1057-64.16. Cannata-Andia JB, Martin-Carro B, Martin-Virgala J, Rodriguez-Carrio J, Bande-Fernandez JJ, Alonso-Montes C, et al. Chronic kidney disease-mineral and bone disorders: pathogenesis and management. Calcif Tissue Int. 2021;108(4):410-22.17. Ritter CS, Slatopolsky E. Phosphate toxicity in CKD: the killer among us. Clin J Am Soc Nephrol. 2016;11(6):1088-100.18. Rastogi A, Bhatt N, Rossetti S, Beto J. Management of hyperphosphatemia in end-stage renal disease: a new paradigm. J Ren Nutr. 2021;31(1):21-34.19. Fujii H, Joki N. Mineral metabolism and cardiovascular disease in CKD. Clin Exp Nephrol. 2017;21(Suppl 1):53-63.20. Mace ML, Gravesen E, Hofman-Bang J, Olgaard K, Lewin E. Key role of the kidney in the regulation of fibroblast growth factor 23. Kidney Int. 2015;88(6):1304-13.21. Dhayat NA, Ackermann D, Pruijm M, Ponte B, Ehret G, Guessous I, et al. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function. Kidney Int. 2016;90(3):648-57.22. Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int. 2014;85(1):142-50.23. Komaba H, Kaludjerovic J, Hu DZ, Nagano K, Amano K, Ide N, et al. Klotho expression in osteocytes regulates bone metabolism and controls bone formation. Kidney Int. 2017;92(3):599-611.24. Rysz J, Franczyk B, Rokicki R, Gluba-Brzozka A. The Influence of dietary interventions on chronic kidney disease-mineral and bone disorder (CKD-MBD). Nutrients. 2021;13(6):2065.25. Hu MC, Kuro-o M, Moe OW. Klotho and chronic kidney disease. Contrib Nephrol. 2013;180:47-63.26. Covic A, Vervloet M, Massy ZA, Torres PU, Goldsmith D, Brandenburg V, et al. Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes Endocrinol. 2018;6(4):319-31.27. Chiang C. The use of bone turnover markers in chronic kidney disease-mineral and bone disorders. Nephrology (Carlton). 2017;22Suppl 2:11-3.28. Pimentel A, Urena-Torres P, Zillikens MC, Bover J, Cohen-Solal M. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Kidney Int. 2017;92(6):1343-55.29. Cohen A, Mathiasen VD, Schon T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655.30. Nigwekar SU, Tamez H, Thadhani RI. Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD). Bonekey Rep. 2014;3:498.31. Bover J, Bailone L, Lopez-Baez V, Benito S, Ciceri P, Galassi A, et al. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol. 2017;30(5):677-87.32. Khairallah P, Nickolas TL. Management of Osteoporosis in CKD. Clin J Am Soc Nephrol. 2018;13(6):962-9.33. Hsu CY, Chen LR, Chen KH. Osteoporosis in patients with chronic kidney diseases: a systemic review. Int J Mol Sci. 2020;21(18):6846.34. Peres LA, Percio PP. Mineral and bone disorder and vascular calcification in patients with chronic kidney disease. J Bras Nefrol. 2014;36(2):201-7.35. Ogawa T, Nitta K. Pathogenesis and management of vascular calcification in patients with end-stage renal disease. Contrib Nephrol. 2018;196:71-7.36. Nelson AJ, Raggi P, Wolf M, Gold AM, Chertow GM, Roe MT. Targeting vascular calcification in chronic kidney disease. JACC Basic Transl Sci. 2020;5(4):398-412.37. Vervloet M, Cozzolino M. Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int. 2017;91(4):808-17.38. Reiss AB, Miyawaki N, Moon J, Kasselman LJ, Voloshyna I, D’Avino R, Jr., et al. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies. Atherosclerosis. 2018;278:49-59.39. Iseri K, Dai L, Chen Z, Qureshi AR, Brismar TB, Stenvinkel P, et al. Bone mineral density and mortality in end-stage renal disease patients. Clin Kidney J. 2020;13(3):307-21.40. Kim H, Lee J, Lee K-B, Kim Y-H, Hong N, Park JT, et al. Low bone mineral density is associated with coronary arterial calcification progression and incident cardiovascular events in patients with chronic kidney disease. Clin Kidney J. 2021;2021:sfab138.41. Elias RM, Dalboni MA, Coelho ACE, Moyses RMA. CKD-MBD: from the pathogenesis to the identification and development of potential novel therapeutic targets. Curr Osteoporos Rep. 2018;16(6):693-702.42. Sprague SM, Martin KJ, Coyne DW. Phosphate balance and CKD-mineral bone disease. Kidney Int Rep. 2021;6(8):2049-58.43. Jovanovich A, Kendrick J. Personalized management of bone and mineral disorders and precision medicine in end-stage kidney disease. Semin Nephrol. 2018;38(4):397-409.44. Vervloet MG, van Ballegooijen AJ. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 2018;93(5):1060-72.45. Bover J, Aguilar A, Arana C, Molina P, Lloret MJ, Ochoa J, et al. Clinical approach to vascular calcification in patients with non-dialysis dependent chronic kidney disease: mineral-bone disorder-related aspects. Front Med (Lausanne). 2021;8:642718.46. Taketani Y, Koiwa F, Yokoyama K. Management of phosphorus load in CKD patients. Clin Exp Nephrol. 2017;21(Suppl 1):27-36.47. Barreto FC, Oliveira RA, Oliveira RB, Jorgetti V: Pharmacotherapy of chronic kidney disease and mineral bone disorder. Expert Opin Pharmacother. 2011;12(17):2627-40.48. Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int. 2013;83(5):959-66.49. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26-36.50. Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018;8:CD006023.51. Copland M, Komenda P, Weinhandl ED, McCullough PA, Morfin JA. Intensive hemodialysis, mineral and bone disorder, and phosphate binder use. Am J Kidney Dis. 2016;68(5S1):S24-32.52. Zhan Z, Smyth B, Toussaint ND, Gray NA, Zuo L, de Zoysa JR, et al. Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study. BMC Nephrol. 2019;20(1):258.53. Kim HW, Kim SH, Kim YO, Jin DC, Song HC, Choi EJ, et al. Impact of dialysate calcium concentration on clinical outcomes in incident hemodialysis patients. Medicine (Baltimore). 2015;94(40):e1694.54. Chen W, Bushinsky DA. Chronic kidney disease: KDIGO CKD-MBD guideline update: evolution in the face of uncertainty. Nat Rev Nephrol. 2017;13(10):600-2.55. Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, et al. Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial. J Am Soc Nephrol. 2014;25(1):175-86.56. Bover J, Urena-Torres P, Mateu S, DaSilva I, Gracia S, Sanchez-Baya M, et al. Evidence in chronic kidney disease-mineral and bone disorder guidelines: is it time to treat or time to wait? Clin Kidney J. 2020;13(4):513-21.57. Keung L, Perwad F. Vitamin D and kidney disease. Bone Rep. 2018;9:93-100.58. Bover J, Ureña-Torres P, Laiz Alonso AM, Torregrosa J-V, Rodríguez-García M, Castro-Alonso C, et al. Osteoporosis, bone mineral density and CKD-MBD (II): therapeutic implications. Nefrología (English Edition). 2019;39(3):227-42.59. Greeviroj P, Kitrungphaiboon T, Katavetin P, Praditpornsilpa K, Eiam-Ong S, Jaber BL, et al. Cinacalcet for treatment of chronic kidney disease-mineral and bone disorder: a meta-analysis of randomized controlled trials. Nephron. 2018;139(3):197-210.60. Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab. 2013;98(12):4834-44.61. Urena-Torres P, Bridges I, Christiano C, Cournoyer SH, Cooper K, Farouk M, et al. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transplant. 2013;28(5):1241-54.62. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26(4):1327-39.63. Moschella C. Chronic kidney disease-mineral and bone disorder: guidelines for diagnosis, treatment, and management. JAAPA. 2016;29(7):21-9.64. Hanudel MR, Moe SM, Saluskt IB. Pathophysiology and treatment of chronic kidney disease-mineral and bone disorder. In: Clifford J. Rosen MD, editors. Primer on the metabolic bone diseases and disorders of mineral metabolism, ninth edition. Hoboken, New Jersey: Wiley; 2019. p.695-702.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.